| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8394410 | Toxicon | 2018 | 16 Pages |
Abstract
OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry, Genetics and Molecular Biology (General)
Authors
Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini,